Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 1/20 | 0.51 |
| ▸ | HTR2C | P28335 | 1/20 | 0.51 |
| ▸ | HTR2B | P41595 | 1/20 | 0.51 |
| ▸ | SLC9A1 | P19634 | 6/20 | 0.48 |
| ▸ | PARP1 | P09874 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | GPR88 | Q9GZN0 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4133997 | 1.00 | HTR2A (0.51) | HTR2AHTR2CHTR2BSLC9A1PARP1 | |
| SCHEMBL7000145 | 0.85 | FFAR1 (0.49) | HTR2AHTR2CHTR2BALDH1A1GPR88 | |
| SCHEMBL14549996 | 0.85 | FFAR1 (0.49) | HTR2AHTR2CHTR2BALDH1A1GPR88 | |
| SCHEMBL31684351 | 0.85 | FFAR1 (0.49) | HTR2AHTR2CHTR2BALDH1A1GPR88 | |
| SCHEMBL4134145 | 0.85 | FFAR1 (0.49) | HTR2AHTR2CHTR2BALDH1A1GPR88 | |
| SCHEMBL5679362 | 0.85 | FFAR1 (0.49) | HTR2AHTR2CHTR2BALDH1A1GPR88 | |
| SCHEMBL18631695 | 0.85 | FFAR1 (0.49) | HTR2AHTR2CHTR2BALDH1A1GPR88 | |
| SCHEMBL3028218 | 0.85 | FFAR1 (0.49) | HTR2AHTR2CHTR2BALDH1A1GPR88 | |
| SCHEMBL14480293 | 0.85 | FFAR1 (0.49) | HTR2AHTR2CHTR2BALDH1A1GPR88 | |
| SCHEMBL4205894 | 0.85 | FFAR1 (0.49) | HTR2AHTR2CHTR2BALDH1A1GPR88 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250319063-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT P53 FUNCTION | PMV PHARMACEUTICALS, INC. | 2025-10-16 | — | — | US | disclosed |
| US-20090203750-A1 | 5-HT2C Receptor Agonists as Anorectic Agents | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2009-08-13 | — | — | US | disclosed |
| WO-2007025144-A1 | 5-HT2C RECEPTOR AGONISTS AS ANORECTIC AGENTS | UNIVERSITY OF ILLINOIS - CHICAGO (US) | 2007-03-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250319063-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT P53 FUNCTION | TP53, TP53BP1, KRAS | HTR2A 4349/4885HTR2C 4327/4885HTR2B 4678/4885 |
| US-20090203750-A1 | 5-HT2C Receptor Agonists as Anorectic Agents | HTR2C, HTR2A, HTR5A | HTR2A 2/4885HTR2C 1/4885HTR2B 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.